Recent News

• 06.02.2026 - Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
• 05.27.2026 - bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
• 05.12.2026 - bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
• 05.08.2026 - bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
• 04.28.2026 - bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
• 04.14.2026 - New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

Recent Filings

• 06.02.2026 - EX-99.1 EX-99.1
• 06.02.2026 - 8-K Current report
• 05.27.2026 - EX-99.1 EX-99.1
• 05.27.2026 - 8-K Current report
• 05.20.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.14.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.12.2026 - 8-K Current report
• 05.12.2026 - EX-99.1 EX-99.1
• 05.12.2026 - EFFECT Notice of Effectiveness
• 05.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]